This article is about the recent and profound changes in the conceptualization of dementia, especially the turn towards prevention. The main argument is that more attention needs to be paid to “situated prevention” — the framing of internationally circulating data on the “new dementia” in different contexts. After introducing some of the more problematic issues related to the “new dementia,” a first comparison of major preventive clinical trials in Europe and in North America will be provided. The major insight stemming from situating the global message of preventing dementia is recognition of the responsibility researchers and policy makers bear with respect to the implicit and potential moral narratives in emerging scientific landscapes.
Get full access to this article
View all access options for this article.
References
1.
D. F.McGowin, Living in the Labyrinth: A Personal Journey through the Maze of Alzheimer's Disease (New York: Delacorte Press, 1993).
2.
B.Reisberg, A Guide to Alzheimer's Disease (New York: The Free Press, 1981); J.Gubrium, Oldtimers and Alzheimer's: The Descriptive Organization of Senility (Greenwich: Jai Press, 1986). Note: In the following I will use “dementia” and “Alzheimer's disease” (AD) interchangeably (employing the common, more colloquial use of the terms), although, in reality, a distinction needs to be made: it should be stated that AD is a syndrome, the most common form of a dementia and, since the 1980s, has meant the early and late onset form. The term was coined in 1910 by Kraepelin who, at that time, was referring to the early-onset, pre-senile form of the disease (see J.Ballenger, Self, Senility and Alzheimer's Disease in Modern America: A History [Johns Hopkins University Press, 2006]).
3.
R. C.Adelman, “The Alzheimerization of Aging,”Gerontolo-gist35, no. 4 (1995): 526-532; R. C.Adelman, “The Alzheimerization of Aging: A Brief Update,”Experimental Gerontology33, nos. 1-2 (1998): 155-157.
4.
R. L.Beard, Living with Alzheimer's: Managing Memory Loss, Identity, and Illness (New York: New York University Press, 2016).
5.
Another major shift in the understanding of the dementia syndrome preceded the two changes here described as part of the “new dementia”: a widening of the category once exclusively steeped in a cognitive paradigm, which now integrated once-peripherical behavioral symptoms into the main syndrome. See A.Leibing, “From the Periphery to the Center: Treating Noncognitive, Especially Behavioral and Psychological, Symptoms of Dementia,” in J.Ballenger, P.White-house, C.Lyketsos, P.Rabins, and J.Karlawish, eds., Treating Dementia: Do We Have a Pill for That? (Baltimore: The Johns Hopkins University Press, 2009): 74-97.
6.
R.Peters, “The Prevention of Dementia,”International Journal of Geriatric Psychiatry24, no. 5 (2009): 452–458.
7.
F. E.Taragano, R. F.Allegri, H.Krupitzki, D.Sarasola, C. M.Serrano, and C.Lyketsos, “Mild Behavioral Impairment and Risk of Dementia,”Neurology70 (2008): A282.
8.
See, e.g., V. A.Kral, “Senescent Forgetfulness: Benign and Malignant,”Canadian Medical Association Journal86 (1962): 257-260; see J.Golomb, A.Kluger, and S. H.Ferris, “Mild Cognitive Impairment: Historical Development and Summary of Research,”Dialogues in Clinical Neuroscience6, no. 4 (2004): 351-367.
9.
See J.Ballenger, Self, Senility and Alzheimer's Disease in Modern America: A History (Johns Hopkins University Press, 2006); A.Leibing, “Narrowing Worlds: On Biography and Alzheimer's Disease in Brazil,” in A.Leibing, ed., The Medical Anthropologies in Brazil (Berlin: VWB-Verlag, 1997): 221-242.
10.
F.Vidal, “Brainhood, Anthropological Figure of Modernity,”History of the Human Sciences22, no. 1 (2009): 5-36; S. J.Williams, S.Katz, and P.Martin, “Neuroscience and Medicalisation: Sociological Reflections on Memory, Medicine and the Brain,” in M.Pickersgill and I.van Keulen, eds., Sociological Reflections on the Neurosciences (Emerald Group Publishing Limited, 2011): at 231-254.
P.Whitehouse, “The Diagnosis and Treatment of Alzheimer's: Are We Being Irresponsible?” in M.Boenink, H.van Lente, and E.Moors, eds., Emerging Technologies for Diagnosing Alzheimer's Disease, Innovating with Care (Palgrave Macmillan, 2016): at 21-39; M.Lock, “Detecting Amyloid Biomarkers: Embodied Risk and Alzheimer Prevention,”Biosocieties8, no. 2 (2013): 107-123; see Leibing, supra note 5; A.Leibing, “The Earlier the Better: Alzheimer's Prevention, Early Detection, and the Quest for Pharmacological Interventions,”Culture, Medicine & Psychiatry38, no. 2 (2014): 217-236.
See Leibing, supra note 13; A.Leibing, “Tense Prescriptions? Alzheimer Medications and the Anthropology of Uncertainty,”Transcultural Psychiatry46, no. 1 (2009): 180-206; Leibing, supra note 13; A.Leibing, “Dementia in the Making: Early Detection and the Body/Brain in Alzheimer's Disease,” in A.Swinnen M. and Schweda, eds., Popularizing Dementia, Public Expressions and Representations of Forgetfulness (Bielefeld: Transkript, 2015): at 275-294; A.Leibing, “On Short Cuts: The Complexity of Studying the Early Diagnosis and Prevention of Alzheimer's Disease,” in M.Boening, H.van Lente, and E.Moors, eds., Emerging Technologies for Diagnosing Alzheimer's Disease: Innovating with Care (Palgrave, 2016): 41-62.
16.
Z. S.Khachaturian and A. S.Khachaturian, “The Paradox of Research on Dementia-Alzheimer's Disease,”Journal of Prevention of Alzheimer's Disease3, no. 4 (2016): 189-191.
17.
M.Richards and C.Brayne, “What Do We Mean by Alzheimer's Disease?”BMJ341 (2010): at 865.
18.
P.Molin and K.Rockwood, “The New Criteria for Alzheimer's Disease: Implications for Geriatricians,”Canadian Geriatrics Journal19, no. 2 (2016): 66-73, at 70.
19.
A.Alzheimer, “Über eine eigenartige Erkrankung der Hirnrinde,”Allg Zschr Psychiatr Psych Gerichtl Med64 (1907): 146-148.
20.
G.Strobel, “After Solanezumab: Where Should Alzheimer's Research Go?”Alzforum, January31, 2017, available at <https://www.alzforum.org/news/conference-coverage/after-solanezumab-where-should-alzheimers-research-go> (last visited August 7, 2018). This does not mean that ß amyloid-based medications have been abandoned. In a recent article with the title “Anti-amyloid drug pipeline shows no sign of drying up” (see M. B.Rogers, “Anti-amyloid Drug Pipeline Shows No Sign of Drying Up,”Alzforum, available at <http://www.alzforum.org/news/conference-coverage/anti-amyloid-drug-pipeline-shows-no-sign-drying> (last visited August 7, 2018), one researcher explained that many other mechanisms interact with amyloid processes: “Instead of a linear amyloid cascade, it's more of a swirling eddy.” It is too early to see whether this more holistic view will later on be part of conceptualizing new classes of drugs and how the multiple factors will be translated into marketing and public health campaigns.
R. L.Kane, “Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia,”AHRQ Publication no. 17-EHC008-EF (2017); K.Anstey and R.Peters, “Oversimplification of Dementia Risk Reduction Messaging Is a Threat to Knowledge Translation in Dementia Prevention Research,”Journal of Prevention of Alzheimer's Disease5, no. 1 (2018): 2-4.
23.
R. A.Sperlinget al., “Toward Defining the Preclinical Stages of Alzheimer's Disease,”Alzheimer's & Dementia7, no. 3 (2011): 280-292, at 282.
24.
See, e.g., J.Attems and K. A.Jellinger, “The Overlap between Vascular Disease and Alzheimer's Disease: Lessons from Pathology,”BMC Medicine12 (2014): 206; see also author Leibing (2014), supra note 13; Leibing (2015, 2016), supra note 13; but see Anstey and Peters, supra note 22.
25.
See Leibing, supra note 13.
26.
For a more detailed analysis, see A.Petersen and D.Lupton, The New Public Health: Health and Self in the Age of Risk (London: Sage, 1997); K.Bell, D.McNaughton, and A.Salmon, eds., Alcohol, Tobacco and Obesity: Morality, Mortality and the New Public Health (London: Routledge, 2011); S.Alvarez, Prévention et vieillissement: l'expérience individuelle du vieillissement face à la norme contemporaine du ”bien vieillir,”Ph.D. thesis in Sociologie, Université de Grenoble, France, 2014; J. K.Shim, Heart-Sick: The Politics of Risk, Inequality, and Heart Disease (New York: New York University Press, 2014); among others.
27.
A. E.Clarkeet al., “Biomedicalization: Technoscientific Transformations of Health, Illness and U.S. Biomedicine,”American Sociological Review68, no. 2, (2003): 161-194.
28.
See Petersen and Lupton, supra note 26; Bell, McNaughton and Salmon, supra note 26, at 201; K.Bell and J.Green, “On the Perils of Invoking Neoliberalism in Public Health Critique,”Critical Public Health26, no. 3 (2016): 239-243; see also A.Leibing and A.Kampf, “Neither Body nor Brain: Comparing Attitudes to Prostate Cancer and Alzheimer's Disease,”Body & Society19, no. 4 (2013): 61-91, at 65ff.
29.
See, e.g., M.Foucault, “Technologies of the Self,” in L. H.Martin, H.Gutman, and P. H.Hutton, eds., Technologies of the Self: A Seminar with Michel Foucault (Amherst, MA: The University of Massachusetts Press, 1988): 16-49; B.Cruikshank, “Revolutions Within: Self-Government and Self-Esteem,” in A.Barry, T.Osborne, and N.Rose, eds., Foucault and Political Reason: Liberalism, Neo-Liberalism, and Rationalities of Government (Chicago, IL: University of Chicago Press, 1996); A.Petersen, “Risk, Governance and the New Public Health,” in A.Petersen and R.Bunton, eds., Foucault, Health and Medicine (London/New York: Routledge, 1998): 189-206; E.Hache (2007) “La responsabilité, une technique de gouvernementalité néolibérale?”Raisons politiques4, no. 28 (2007): 49-65.
30.
See Bell and Green, supra note 28; V.Ridde, “Reducing Social Inequalities in Health: Public Health, Community Health or Health Promotion?”Health Promotion and Education14, no. 2 (2007): 63-67, 111-114.
31.
C.Mayes, The Biopolitics of Lifestyle: Foucault, Ethics and Healthy Choices (London/New York, Routledge, 2016): at 4.
32.
R. A.Aronowitz, “The Converged Experience of Risk and Disease,”Milbank Quarterly87 (2009): 417–442; also M. J.Kreiner and L. M.Hunt, “The Pursuit of Preventive Care for Chronic Illness: Turning Healthy People into Chronic Patients,”Sociology of Health and Illness36, no. 6 (2013): 870-884.
33.
See, e.g., Mayes, supra note 31.
34.
S.Katz, “Active and Successful Aging: Lifestyle as a Geronto-logical Idea,”Recherches sociologiques et anthropologiques44, no. 1 (2013): 33-49.
35.
See, e.g., S.Lamb, ed., Successful Aging? Global Perspectives on a Contemporary Obsession (London: Rutgers University Press, 2017).
D.Haraway, “Situated Knowledges: The Science Question in Feminism and the Privilege of Partial Perspective,”Feminist Studies14, no. 3 (1988): 575-599.
39.
K.Knorr-Cetina, Epistemic Cultures, How the Sciences Make Knowledge (Cambridge, MA: Harvard University Press, 1999).
40.
See, for example, A.Leibing, “The Earlier the Better: Alzheimer's Prevention, Early Detection, and the Quest for Pharmacological Interventions,”Culture, Medicine & Psychiatry38, no. 2 (2014): 217-236. A.Leibing, “From the Periphery to the Center: Treating Noncognitive, Especially Behavioral and Psychological, Symptoms of Dementia,” in J.Ballenger, P.Whitehouse, C.Lyketsos, P.Rabins, and J.Karlawish, eds., Treating Dementia: Do We Have a Pill for That? (Baltimore: The Johns Hopkins University Press, 2009): 74-97.
It is possible that parts of the Canadian research community are more critical regarding the ‘new dementia’ when compared with U.S. American tendencies: “The 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) recommended that the criteria for MCI due to AD be used cautiously and only in specialized clinical practice. Specifically, the CCCDTD4 considered it premature to refer to brain amyloidosis as an asymptomatic state of AD and rejected the label “preclinical AD” as proposed by the NIA-AA. Moreover, ethical and financial impact of its use would be considerable. IWG's definition of “asymptomatic at risk” has been endorsed only for research purposes” (Molin and Rockwood, 2016):67.
PREVENT Dementia Study, “Welcome to the PREVENT Dementia Study,” (n.d.), available at <http://preventdementia.co.uk/> (last visited August 7, 2018).
48.
See Anstey and Peters, supra note 22.
49.
The Alzheimer's Association explains the heart-head connectionon their website, suggesting additionally an explanation of why some people show no symptoms of dementia, even when after autopsy they were found to have the typical biomarkers, neurofibrillary plaques and amyloid tangles in their brain (and vice versa — dementia, but no biomarkers), an apparent contradiction that has been used by a number of critical social scientists in order to deconstruct dominant dementia models: “Several conditions known to increase the risk of cardiovascular disease — such as high blood pressure, diabetes and high cholesterol — also increase the risk of developing Alzheimer's. Some autopsy studies show that as many as 80 percent of individuals with Alzheimer's disease also have cardiovascular disease. (…) Some autopsy studies suggest that plaques and tangles may be present in the brain without causing symptoms of cognitive decline unless the brain also shows evidence of vascular disease” (see <http://www.alz.org/research/science/alzheimers_prevention_and_risk.asp> [last visited August 7, 2018]).
50.
See M.Baker, “In Biomarkers We Trust?”Nature Biotechnology23, no. 3 (2005): 297-304; I.Metzler, “Biomarkers and Their Consequences for the Biomedical Profession: A Social Science Perspective,”Future Medicine7, no. 4 (2010): 407-420.
51.
After Metzler (id.).
52.
See Baker, supra note 50.
53.
See, e.g., K.Applbaum, “Is Marketing the Enemy of Pharmaceutical Innovation?”Hastings Center Report39, no. 4 (2009): 13-17; S.Sismondo, “Pharmaceutical Company Funding and Its Consequences: A Qualitative Systematic Review,”Contemporary Clinical Trials29 (2008): 109-113.
GAP (Global Alzheimer's Platform, (n.d., available at <http://globalalzplatform.org/> (last visited August 7, 2018); see also J.Cummingset al., “Re-engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network,”Journal of Prevention of Alzheimer's Disease3, no. 2 (2016): 114-120.
56.
See Molin and Rockwood, supra note 18, at 66.
57.
Peter Whitehouse, personal information.
58.
D. C.Hallin, “Comparing Mass Media in Europe and the United States,”Insights on Law & Society5, no. 3 (2005): 1-4.
59.
J. A.Greenberg and D.Herzberg, “Hidden in Plain Sight Marketing Prescription Drugs to Consumers in the Twentieth Century,”American Journal of Public Health100, no. 5 (2010): 793-803.
60.
L. M.Hunt, M.Kreiner, and H.Brody, “The Changing Face of Chronic Illness Management in Primary Care: A Qualitative Study of Underlying Influences and Unintended Outcomes,”Annals of Family Medicine10, no. 5 (2012): 452-460.
61.
S.Stringhiniet al., “Socioeconomic Status and the 25 × 25 Risk Factors as Determinants of Premature Mortality: A Multicohort Study and Meta-analysis of 1·7 Million Men and Women,”The Lancet389, no. 100075 (2017): 1229-1237.
62.
K. C.Manton, X. L.Gu, and S.V.Ukraintseva, “Declining Prevalence of Dementia in the U.S. Elderly Population,”Advances in Gerontology16 (2005): 30-37.
63.
E. M. C.Schrijvers, B. F. J.Verhaaren, P. J.Kroudstaal, A.Hofman, M. A.Ikram, and M. M. B.Breteler, “Is Dementia Incidence Declining? Trends in Dementia Incidence Since 1990 in the Rotterdam Study,”Neurology87, no. 19 (2012): 1456-1463.
64.
C.Qiu, E.von Strauss, L.Backman, B.Winblad, and L.Fratiglioni, “Twenty-Year Changes in Dementia Occurrence Suggest Decreasing Incidence in Central Stockholm, Sweden,”Neurology80, no. 20 (2013): 1888-1894.
65.
F. E.Matthews, A.Arthur, L. E.Barnes, J.Bond, C.Jagger, L.Robinson, and C.Brayne, “A Two-Decade Comparison of Prevalence of Dementia in Individuals Aged 65 Years and Older from Three Geographical Areas of England: Results of the Cognitive Function and Ageing Study I and II,”The Lancet382, no. 9902 (2013): 1405-1412.
66.
V.Hachinski and L.Sposato, “Dementia: From Muddled Diagnoses to Treatable Mechanisms,”Brain136 (2013): 2652-2656.
